Globe Newswire

August 1, 2024

Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development

Outpace in the Press

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

March 21, 2021

In The News

Endpoints News

A pair of Lyell founders look to shift the cell therapy paradigm — and they've got $30M to get their plan off the ground

DOWNLOAD

News

All

April 5, 2021

In The News

Forbes

Outpace Bio raises $30 Million to design next generation cell therapies

News

March 31, 2021

Public Relations

Globe Newswire

Creating next generation smart cell therapies: Outpace Bio receives $30 million in Series A funding led by ARTIS Ventures and Lyell Immunopharma Inc

PR

March 21, 2021

In The News

Endpoints News

A pair of Lyell founders look to shift the cell therapy paradigm — and they've got $30M to get their plan off the ground

News

March 21, 2021

In The News

Endpoints News

A pair of Lyell founders look to shift the cell therapy paradigm — and they've got $30M to get their plan off the ground

News

November 5, 2024

Public Relations

Globe Newswire

Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

PR

August 1, 2024

Public Relations

Globe Newswire

Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development

PR

April 4, 2024

Public Relations

Globe Newswire

Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting

PR

October 31, 2023

Public Relations

Globe Newswire

Outpace Bio to present new data on tumor-restricted IL-12 designed leveraging OutSmart technology to enhance solid tumor T cell therapies at SITC 2023

PR

May 22, 2023

Public Relations

Globe Newswire

Outpace Bio expands Seattle presence with cell therapy research hub & collaborations with leading experts in protein design & cancer immunotherapy

PR

May 18, 2023

Public Relations

Globe Newswire

Outpace Bio to present new data on OutSmart™ IL-2/15, a CAR T cell-produced designed cytokine with tumor-localized immune cell activity, at the 2023 annual meeting of the American Society of Gene & Cell Therapy (ASGCT)

PR

November 19, 2024

Publications

Society for Immunotherapy of Cancer (SITC)

Publications

April 7, 2024

Publications

American Association for Cancer Research (AACR)

In vitro modeling of antigen-driven exhaustion in human CAR T cells

Publications

April 7, 2024

Publications

American Association for Cancer Research (AACR)

"Development of tumor-restricted IL-12 with antigen-dependent expression and localized IL-12 activity"

Publications

April 7, 2024

Publications

American Association for Cancer Research (AACR)

OPB-101: An optimized mesothelin-specific CAR T cell product expressing CD8-targeted IL-2/15 and engineered to resist T cell exhaustion

Publications

November 3, 2023

Publications

Society for Immunotherapy of Cancer (SITC)

Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies

Publications

October 9, 2023

Publications

Cancer Cell

Building smart CAR T cell therapies: The path to overcome current challenges

Publications

Press Kit

The Outpace Press Kit is designed to help journalists research Outpace. Please contact our communications team if you need more information or to schedule an interview.

Download

Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development

Outpace in the Press

Press Kit

Connect With Us